Últimas noticias sobre Sonim Technologies (NASDAQ:SONM) Bolsa

Sonim Technologies

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

TSMC y otras acciones destacaron en el premercado tras reportar ganancias récord. Descubre los mayores ganadores y perdedores.

Acciones de Taiwan Semiconductor (TSM) suben alrededor del 5%; 20 acciones en movimiento en el premercado de EE.UU.

Sonim Technologies Inc

SONM (BEP-20)

WIIM

American Shared Hospital Services shares are trading lower after the company reported Q1 financial results.

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Outperform and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

ADCT

RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target

KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has outperformed the market over the past 10 years by 7.79% on an annualized basis producing an average annual return of 18.48%. Currently, KKR has a market capitalization of $111.67 billion. 
Buying $100 In KKR: If an investor had bought $100 of KKR stock 10 years ago, it would be worth $542.32 today based on a price of $125.39 for KKR at the time of writing.
<h3>KKR's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747323922_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In KKR 10 Years Ago Would Be Worth Today

Rosenblatt analyst Kevin Cassidy maintains Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) with a Buy and maintains $4 price target.

INVZ

Rosenblatt Maintains Buy on Innoviz Technologies, Maintains $4 Price Target

<ul>
<li>Co-development of precision RNA therapeutics for inherited hearing loss treatment</li>
</ul>
SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company&nbsp;to develop and commercialize novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.
The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
If Lilly exercises all available options under the agreement, the total deal value could reach more than $1.3 billion, as well as separate royalties on product sales. In line with the mutual understanding between the two companies, the upfront payment was not disclosed.&nbsp;

Contracts

Rznomics Enters Global Licensing Agreement With Eli Lilly For RNA-editing Therapeutics; If Lilly Exercises All Available Options Under The Agreement, The Total Deal Value Could Reach More Than $1.3B, As Well As Separate Royalties On Product Sales; The Upfront Payment Was Not Disclosed

Rosenblatt analyst Kevin Cassidy maintains Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Neutral and maintains $3 price target.

BZAI

Rosenblatt Maintains Neutral on Blaize Holdings, Maintains $3 Price Target

Workhorse Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares are trading lower on Thursday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45432194/workhorse-group-reports-first-quarter-2025-results" rel="noreferrer noopener">reported first-quarter results</a>.
Workhorse registered quarterly earnings per share of $4.68 loss, missing the street view of a $3.44 loss. Quarterly sales of $640,920 missed the analyst consensus estimate of $2.35 million.
Quarterly sales decreased from $1.34 million&nbsp;primarily due to the Aero divestiture and decreased W4 CC and W56 truck sales.
During the three months ended March 31, Workhorse said that an institutional investor converted $5.9&nbsp;million of principal into common stock, and the company recorded a $3.3 million fair value net loss in interest expense.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/05/45430250/tesla-rival-baidu-expands-apollo-go-robotaxi-to-europe-sets-sights-on-turkey-amid-rising-competition-report" rel="noreferrer noopener">Tesla Rival Baidu Expands Apollo Go Robotaxi To Europe, Sets Sights On Turkey Amid Rising Competition: Report</a>
&#8220;Thus far in 2025, Workhorse has received purchase orders for a total of 27 W56 step vans, in both 178- and 208-inch wheelbases, as well as six W4 CC/W750 trucks,&#8221; said Workhorse CEO Rick Dauch.
&#8220;We are also currently negotiating with several potential customers regarding the purchase of additional W56 trucks,&#8221; the CEO added.
The company&#8217;s gross loss in the quarter under review narrowed to $4.523 million, compared with loss of $6.103 million a year ago.
As of March 31, the company had $2.6 million of cash and cash equivalents and $27.9 million in restricted cash net.
Workhorse <a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_ad867729314fa3424217b547b9a3dfed/workhorse/db/591/5720/presentation/WKHS+Q1+2025+Earnings+Presentation+5-14-25.pdf" rel="noreferrer noopener">said </a>it is working to save cash and extend its financial runway. It plans to sell more trucks in the second quarter of 2025 than it did in all of 2024.
The company aims to cut its monthly cash burn to $2.8 million by end-2024. Cost cuts include major workforce reductions and other savings steps.
Price Action: At last check Thursday, the company&#8217;s share price was down 7.36% at 92 cents. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020" target="_blank" rel="noreferrer noopener">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a></li>
</ul>

Earnings

Equities

General

WKHS

Workhorse Stock Slides After Q1 Miss, Plans To Cut Workforce To Curb Cash Burn

Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) with a Overweight and lowers the price target from $8 to $7.

Cantor Fitzgerald Maintains Overweight on Exagen, Lowers Price Target to $7

Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) is riding its strongest rally in two years &#8211; and now, it's firing on all cylinders with a fresh catalyst: a <a href="https://www.benzinga.com//node/45410939">$6 billion stock buyback plan</a>. 
The announcement, coupled with a string of recent wins, has sent AMD shares soaring over 21% in the past month.
<h2 class="wp-block-heading">AMD Stock Technical Breakout In Progress</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png" alt="" class="wp-image-916673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102207/Screenshot-2025-05-15-at-7.35.26-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
AMD has broken past resistance at around $115 and is charging toward its 200-day simple moving average (SMA) of $127.18. With the stock trading above its five, 20, and 50-day exponential moving averages, technical signals remain bullish. 
The MACD (moving average convergence/divergence) indicator at 4.4 suggests continued buying strength, though the RSI (relative strength index) sitting at the cusp of overbought conditions at 70, flags near-term caution.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png" alt="" class="wp-image-916675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15102219/Screenshot-2025-05-15-at-7.30.30-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Shorter-term indicators still support the momentum. The eight-day SMA at $107.24, the 20-day at $99.23, and the 50-day at $99.21 all sit well below the current price &#8211; reinforcing the trend strength. 
However, the stock has not yet cleared the 200-day SMA, which could act as a crucial test in coming sessions.
Read Also: <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a>
<h2 class="wp-block-heading">Buybacks, Big Deals, And Beating Expectations</h2>
The buyback boost brings AMD's total repurchase firepower to $10 billion, thanks to the existing $4 billion balance from a prior authorization. With $7.31 billion in cash on hand, AMD has room to keep rewarding shareholders.
Momentum has been building fast: the company recently posted first quarter earnings that beat expectations &#8211; $7.44 billion in revenue and 96 cents in adjusted EPS, topping estimates of $7.13 billion and 94 cents, respectively. It also announced a $10 billion data center deal in Saudi Arabia and inked a GPU cluster partnership with TensorWave.
From technical breakout to buyback buzz, AMD's rally has legs &#8211; and the bulls don't seem ready to let go just yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45437643/nvidia-now-worth-35x-intel-after-16-year-surge-and-valuation-gap-keeps-growing">Nvidia Now Worth 35x Intel After 16-Year Surge And Valuation Gap Keeps Growing</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Tech

Best AMD Stock Rally In 2 Years Gets A Buyback Boost

Rosenblatt analyst Blair Abernethy maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Buy and maintains $67 price target.

Rosenblatt Maintains Buy on Dynatrace, Maintains $67 Price Target

Chardan Capital analyst Daniil Gataulin maintains Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) with a Buy and maintains $33 price target.

ADVM

Chardan Capital Maintains Buy on Adverum Biotechnologies, Maintains $33 Price Target

<a href="https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa">https://www.wsj.com/health/pharma/new-allegations-about-timing-of-pfizer-covid-vaccine-passed-to-house-panel-3451ec97?msockid=21c662101c496b42343370ae1de86aaa</a>

'New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel'- WSJ

Cantor Fitzgerald analyst Deepak Mathivanan reiterates Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and maintains $170 price target.

EXPE

Cantor Fitzgerald Reiterates Neutral on Expedia Group, Maintains $170 Price Target

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) stock is trading lower on Thursday in reaction to a media report on a possible investigation for <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45426769/unitedhealth-stock-plunges-over-8-in-after-hours-trading-as-doj-criminal-probe-adds-to-turmoil-after-ceo-shake-up" rel="noreferrer noopener">criminal Medicare fraud</a>.
The Wall Street Journal <a href="https://www.wsj.com/us-news/unitedhealth-medicare-fraud-investigation-df80667f?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo">reported</a>, citing people familiar with the matter, that the healthcare-fraud unit of the Justice Department&#8217;s criminal division is overseeing the investigation, which has been active since at least last summer. 
UnitedHealth&#8217;s latest annual securities filing says the company &#8220;has been involved or is currently involved in various governmental investigations, audits and reviews,&#8221; and flags involved agencies including the Justice Department. 
It doesn&#8217;t specifically mention the criminal, civil and antitrust probes on which the Journal has reported.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44821140/unitedhealth-demands-rapid-repayment-of-cyberattack-relief-loan-billions-providers-say-push-undermines-recovery" rel="noreferrer noopener">UnitedHealth Demands Rapid Repayment Of Cyberattack Relief Loan Billions, Providers Say Push Undermines Recovery</a>
In a statement on Wednesday, the company <a target="_blank" href="https://www.unitedhealthgroup.com/newsroom/2025/2025-05-14-response-may-14-wsj-article.html" rel="noreferrer noopener">said</a>, &#8220;We have not been notified by the Department of Justice of the supposed criminal investigation reported, without official attribution, in the&nbsp;Wall Street Journal today.&#8221;
&#8220;We stand by the integrity of our Medicare Advantage program,&#8221; the company statement continued.
On Tuesday, UnitedHealth CEO Andrew Witty abruptly announced his resignation and suspended its <a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" target="_blank" rel="noreferrer noopener">fiscal year 2025 guidance</a>.
The insurance giant has garnered immense attention following the murder of its insurance unit CEO,&nbsp;Brian Thompson, in New York.
Luigi Mangione, the alleged perpetrator, pleaded not guilty to murder and weapons charges. Police found shell casings at the scene with the words &#8220;deny,&#8221; &#8220;defend,&#8221; and &#8220;depose,&#8221; commonly associated with insurance industry strategies for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42771908/viral-tear-it-all-down-post-sparks-debate-over-unitedhealthcare-practices-alleges-denial-of-icu-care-for-comatose-patient" rel="noreferrer noopener">handling claims and disputes</a>.
According to a media report in February, the Justice Department reportedly launched a civil fraud investigation into&nbsp;UnitedHealth&#8217;s <a target="_blank" href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" rel="noreferrer noopener">Medicare billing practices</a>.
The WSJ&nbsp;<a target="_blank" href="https://www.wsj.com/health/healthcare/unitedhealth-medicare-doj-diagnosis-investigation-66b9f1db?mod=latest_headlines&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">reported</a>&nbsp;that Medicare paid substantial sums to UnitedHealth based on diagnoses added to patients&#8217; records, some of which doctors said were irrelevant or undocumented.
In March, a Special Master recommended granting&nbsp;UnitedHealth&#8217;s&nbsp;motion for summary judgment in a False Claims Act (FCA) case, concluding that the government lacks evidence&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44141489/false-claims-act-case-against-unitedhealth-faces-dismissal-recommendation" rel="noreferrer noopener">to support its allegations</a>.
In April, UnitedHealth got some relief when the Federal Trade Commission (FTC) paused the formal complaint against three major pharmacy benefit managers (PBMs) for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">price of insulin medications</a>.
Analyst Reaction:
<ul class="wp-block-list">
<li>Keybanc maintains UnitedHealth with an Overweight rating, lowering the <a href="https://www.benzinga.com/quote/UNH/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $575 to $450</a>.</li>
<li>Baird maintains UnitedHealth with an Outperform rating, lowering the price target from $510 to $356.</li>
<li>BofA Securities downgrades UnitedHealth from Buy to Neutral and lowers the price target from $560 to $350.</li>
<li>Morgan Stanley maintains UnitedHealth with an Overweight rating, lowering the price target from $563 to $374.</li>
<li>Wells Fargo maintains UnitedHealth with an Overweight, lowering the price target from $677 to $351.</li>
<li>Oppenheimer maintains UnitedHealth with an Outperform rating, lowering the price target from $600 to $400.</li>
<li>Deutsche Bank maintains UnitedHealth with a Buy, lowering the price target from $521 to $362.</li>
<li>JP Morgan maintains UnitedHealth with an Overweight, lowering the price target from $525 to $405.</li>
</ul>
Price Action: UnitedHealth stock is down 7.83% at $283.88 during the premarket session at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45435748/dicks-sporting-goods-to-acquire-foot-locker-at-66-premium" target="_blank" rel="noreferrer noopener">Dick&#8217;s Sporting Goods To Acquire Foot Locker At 66% Premium</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

Legal

Why Is UnitedHealth Stock Trading Lower On Thursday?

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) with a Buy and maintains $20 price target.

SABS

Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $20 Price Target

US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) has outperformed the market over the past 5 years by 17.53% on an annualized basis producing an average annual return of 32.55%. Currently, US Foods Hldg has a market capitalization of $17.33 billion. 
Buying $1000 In USFD: If an investor had bought $1000 of USFD stock 5 years ago, it would be worth $3,907.86 today based on a price of $74.91 for USFD at the time of writing.
<h3>US Foods Hldg's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747323016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

USFD

Here's How Much You Would Have Made Owning US Foods Hldg Stock In The Last 5 Years

Cantor Fitzgerald analyst Ross Osborn reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Overweight and maintains $2 price target.

LUCD

Cantor Fitzgerald Reiterates Overweight on Lucid Diagnostics, Maintains $2 Price Target

Cantor Fitzgerald analyst Kristen Kluska upgrades Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) from Neutral to Overweight and announces $10 price target.

Upgrades

FULC

Cantor Fitzgerald Upgrades Fulcrum Therapeutics to Overweight, Announces $10 Price Target

CNEY

CN Energy Group shares are trading lower after the company reported a 1-for-25 reverse stock split.

Reddit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NASDAQ">RDDT</a>) shares fell 9.4% to $113.55 on Thursday, pulling back after a recent rally that had lifted the stock more than 25% over the past month. The decline follows a 9.2% jump on Wednesday, fueled by the company's strong <a href="https://www.benzinga.com/general/social-media/25/05/45178546/reddit-executives-see-strong-growth-in-q2-and-beyond">first-quarter earnings</a> and upbeat outlook.
What To Know: Reddit recently posted first-quarter earnings of 13 cents per share, beating consensus estimates of 2 cents. Revenue hit $392.36 million, up from $242.96 million a year ago, driven by a 61% surge in ad revenue and a 31% increase in daily active users to 108.1 million. 
Net income <a href="https://www.benzinga.com/general/social-media/25/05/45178546/reddit-executives-see-strong-growth-in-q2-and-beyond">reached $26.2 million</a>, reversing a $575.1 million loss a year prior. Operating cash flow rose to $127.6 million, while gross margin improved to 90.5%.
Read Also: <a href="https://www.benzinga.com/general/sports/25/05/45424475/foot-locker-stock-soars-on-potential-dicks-sporting-goods-deal-report">Foot Locker Stock Soars On Potential Dick&#8217;s Sporting Goods Deal: Report</a>
CEO Steve Huffman touted weekly active users <a href="https://www.benzinga.com/general/social-media/25/05/45151798/reddit-stock-soars-after-better-than-expected-q1-daily-active-uniques-up-31-ad-revenue-up-61-and-more">exceeding 400 million</a>, and Reddit guided second-quarter revenue between $410 million and $430 million. Analysts responded positively: Seaport upgraded Reddit to Buy, Needham and JP Morgan raised their price targets, and consensus remains optimistic on long-term growth.
What Else: Meanwhile, the Kids Online Safety Act was <a href="https://www.theverge.com/news/666729/kids-online-safety-act-reintroduced">reintroduced</a> in the Senate this week. The bill would impose new safety requirements on platforms used by minors and has drawn both support and criticism, with tech firms like Apple Inc backing the measure and civil liberties groups voicing concern over potential censorship.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a>
<h2 class="wp-block-heading">How To Buy RDDT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Reddit&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RDDT has a 52-week high of $230.41 and a 52-week low of $49.13.

RDDT

Reddit (RDDT) Stock Is Down 9% Thursday: What's Going On?

Press Releases

Sonim Technologies Provides Update on Strategic Review Process and Addresses Market Speculation

Sonim Technologies Introduces the XP3plus 5G Feature Flip Phone; Certified for T-Priority

Sonim Technologies Announced as Latest "Verizon Frontline Verified" Partner

UPDATE: Sonim Technologies Announced as Latest "Verizon Frontline Verified" Partner

Sonim Technologies Reports Full Year 2024 Financial Results

Sonim Technologies, Inc. Special Committee Confirms Receipt of Unsolicited Proposal for $4.00 per Share in Cash

Sonim Technologies Announces Engagement with Shareholder Intelligence Services, LLC to Protect Shareholders and Maximize Value

Sonim Technologies Accelerates Expansion Strategy with Strong Momentum in the Second Quarter 2025

Sonim Announces Initial Purchase Orders For XP Pro Thermal Ahead of General Availability

Comments

Sonim Technologies

Noticias

Últimas noticias sobre Sonim Technologies (NASDAQ:SONM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL